<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="905">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351724</url>
  </required_header>
  <id_info>
    <org_study_id>ACOVACT</org_study_id>
    <nct_id>NCT04351724</nct_id>
  </id_info>
  <brief_title>Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)</brief_title>
  <acronym>ACOVACT</acronym>
  <official_title>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaiser Franz Josef Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMZ-Ost Donauspital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otto Wagner Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Hietzing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wilhelminenspital Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled,
      multicenter, open-label basket trial that aims to compare various antiviral treatments for
      COVID-19. Moreover three substudies have been integrated. Currently, patients will be
      randomized to receive (hydroxy-)chloroquine, lopinavir/ritonavir or standard of care.
      Moreover, these patients are eligible for substudy A (randomized to rivaroxaban 5mg 1-0-1 vs.
      standard of care), substudy B (renin-angiotensin (RAS) blockade vs. no RAS blockade for
      patients with blood pressure &gt;120/80mmHg), and substudy C (clazakizumab vs standard of care,
      for patients with respiratory deterioration and high inflammatory biomarkers).

      Endpoints were chosen based on the master protocol published by the World Health Organisation
      and include a 7-point scale of clinical performance, mortality, oxygen requirement (both dose
      and type), duration of hospitalization, viral load and safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three main study arms (antiviral treatments) and three substudies (A, B, C) are planned. The main study arms are exclusive, while patients from the main study arms may participate in one or more substudies.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sustained improvement (&gt;48h) of one point on the WHO Scale</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>The primary endpoint is time to clinical improvement which is defined as time from randomization to an (sustained) improvement of at least one category on two consecutive days compared to the status at randomization measured on a seven-category ordinal scale (proposed by WHO).
The 7-categories of the World Health Organization proposed scale, as follows:
Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities;
Hospitalized, not requiring supplemental oxygen;
Hospitalized, requiring supplemental oxygen;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;
Hospitalized, on invasive mechanical ventilation or ECMO;
Death.
During hospitalization this score will be determined daily (till day 29). If a patient is released from the hospital before day 29, the score will be determined at day 11 and 29 after randomization (depending when the patient was released or by telephone call).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to improvement on WHO Scale</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>The scale described in the primary endpoint is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the ranking on an ordinal scale from baseline</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>The scale described in the primary endpoint is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to discharge or a National Early Warning Score (NEWS) â‰¤2 (maintained for 24h), whichever occurs first</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>the National Early Warning Score includes respiratory rate, oxygen saturation, use of supplemental oxygen, temperature, systolic blood pressure, heart rate and levels of consciousness (AVPU Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in National Early Warning Score (NEWS)</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>The scale described in the primary endpoint is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation free days</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new oxygen use during the trial</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>new oxygen may include insufflation or oxygen mask, high flow oxygen devices, non-invasive ventilation devices or mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of oxygen use during the trial</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days until day 29</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>number of days with requirement of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new mechanical ventilation use during the trial</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation use during the trial</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load/viral clearance</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>obtained by polymerase chain reaction in nasal/oropharyngeal swabs, performed at baseline and then three times a week, if possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>15-day, 29-day mortality</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity - mortality</measure>
    <time_frame>BMI at admission, mortality until day 29</time_frame>
    <description>BMI (kg/m2), within all subjects the impact of obesity on overall mortality will be investigated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity - duration of hospitalization</measure>
    <time_frame>BMI at admission, duration of hospitalization until day 29 or discharge</time_frame>
    <description>BMI (kg/m2) , within all subjects the impact of obesity on the duration of hospitalization will be investigated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity - ICU admission</measure>
    <time_frame>BMI at admission, ICU admission until day 29 or discharge</time_frame>
    <description>BMI (kg/m2) , within all subjects the impact of obesity on ICU admission will be investigated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity - new oxygen use</measure>
    <time_frame>BMI at admission, new oxygen use until day 29 or discharge</time_frame>
    <description>BMI (kg/m2) new oxygen may include insufflation or oxygen mask, high flow oxygen devices, non-invasive ventilation devices or mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-drug interactions with lopinavir/ritonavir</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>lopinavir and ritonavir both interact with numerous other drugs by inhibiting the cytochrome enzymes 3A4. Using commercially available drug-interaction programs, the number and severity grading of drug-drug-interactions will be documented (for instance uptodate interaction tool, medscape). This is an exploratory analysis of drug-drug interactions with the above mentioned substances. severity grading usually encompass &quot;contraindicated&quot;, &quot;serious&quot;, &quot;monitor closely&quot;, &quot;minor&quot; interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin Angiotensin System (RAS) fingerprint</measure>
    <time_frame>Inclusion to day 29, daily evaluation</time_frame>
    <description>for sub-study B only: RAS fingerprint measures metabolites involved in the renin-angiotensin-system. The influence of randomized treatment with candesartan (RAS blockade) will be analyzed</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>(Hydroxy)Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Due to limited availability of the experimental substances, this arm will include both chloroquine and hydroxychloroquine treatment. However, both substances are similar chemically and also with regards to the mechanism of action comparable.
Dosage: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 200mg/50mg 2-0-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients will be treated with &quot;standard of care&quot;, which precludes treatment with lopinavir/ritonavir or (hydroxy-)chloroquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thromboprophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>according to local standard</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAS Blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renin-Angiotensin-System-Blockade (RAS) by candesartan intake starting with 4mg once daily and titrated to normotension patients &gt; 120/80 mmHG are eligible</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-RAS-Blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-RAS blocking antihypertensive agents titrated to normotension Those with normal blood pressure may only be controlled without further treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clazakizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with respiratory deterioration qualify for this treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with respiratory deterioration qualify for this treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine or Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available</description>
    <arm_group_label>(Hydroxy)Chloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>Lopinavir/Ritonavir 200mg/50mg 2-0-2</description>
    <arm_group_label>Lopinavir/Ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best standard of care</intervention_name>
    <description>best standard of care</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thromboprophylaxis</intervention_name>
    <description>as local standard, most likely to be low molecular weight heparin</description>
    <arm_group_label>Thromboprophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>starting dose 4mg once daily, titrated to normotension</description>
    <arm_group_label>RAS Blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-RAS blocking antihypertensives</intervention_name>
    <description>This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others</description>
    <arm_group_label>non-RAS-Blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clazakizumab</intervention_name>
    <description>25mg i.v. single dose, possibly a repeated dose</description>
    <arm_group_label>Clazakizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for clazakizumab</intervention_name>
    <description>sodium chloride bolus infusions as placebo for clazakizumab</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laboratory confirmed infection with SARS-CoV-2 â‰¤72 hours before randomization

          -  Hospitalisation due to SARS-CoV-2 infection (for anti-viral treatment arms)

          -  For &quot;antiviral&quot; therapy because of limited drug supplies: oxygen saturation &lt;94% when
             breathing room air or &gt;3% drop in case of chronic obstructive lung disease

          -  Informed Consent obtained, the patient understands and agrees to comply with the
             planned study procedures, except for substudy C: obtaining informed consent may be
             impossible due to the severe condition of the patient and may be waived

          -  â‰¥18 years of age

          -  For female patients with childbearing potential: willingness to perform effective
             measures of contraception during the study.

          -  Sub-study A: eGFR of &gt;20 mL/min

          -  Sub-study B: outpatients with COVID-19 may be included

          -  Sub-study B: blood pressure â‰¥120/80mmHg in 2 consecutive measurements

          -  Sub-study B: Control group 1: Patients with suspicion of but negative tests for
             COVID-19. This group may consist of hospitalized and non-hospitalized patients.

          -  Sub-study B: control group 2: healthy volunteers

          -  Sub-study C: Signs of respiratory deterioration and progressing inflammation such as
             need for oxygen supplementation to achieve satisfactory blood oxygen saturation
             (sPO2&gt;90% at room air) as well as the need for mechanical ventilation, novel onset of
             uni- or bilateral lung infiltrates in CXR/CT scan, CRP levels &gt;5mg/dL

        Exclusion Criteria:

          -  Moribund or estimated life expectancy &lt;1 month (e.g. terminal cancer, etc.)

          -  Pregnancy or breastfeeding

          -  Severe liver dysfunction (e.g. ALT/AST &gt; 5 times upper limit of normal)

          -  Stage 4 chronic kidney disease or requiring dialysis (except for ritonavir/lopinavir)

          -  Allergy or intolerances to any of the experimental substances -&gt; exclusion for the
             respective treatment arm

          -  Anticipated discharge of hospital within 48 hours (for anti-viral treatment arms)

          -  Contraindications treatment arm 1: chloroquine/ hydroxychloroquine: concomitant
             amiodarone treatment, retinopathy, psoriasis, glucose-6-phosphate deficiency, severe
             cardiomyopathy and known, clinically relevant arrhythmias, porphyria cutanea tarda

          -  Clinically relevant QTc prolongation during screening

          -  Contraindications treatment arm 2: severe hepatic impairment, CYP3A4/5 metabolized
             drugs as deemed relevant by treating physicians, HIV positive

          -  Contraindications treatment arm 3: IgA deficiency

          -  Sub-study A Contraindications: active bleeding or bleeding diathesis, lesion or
             condition considered as major risk factor for bleeding, recent brain or spinal injury,
             recent brain or spinal or ophthalmic surgery, recent intracranial hemorrhage, known or
             suspected esophageal varices, arteriovenous malformations, vascular aneurysms, major
             intraspinal or intracerebral vascular abnormalities.

          -  Sub-study A: ongoing therapeutic anticoagulation, which will continue, according to
             clinical practice

          -  Sub-study B Contraindications chronic heart failure, allergies, hypersensitivities and
             intolerances, severe hepatic impairment and/or cholestasis, concomitant therapy with
             aliskiren-containing medications (for patients with diabetes mellitus or a
             GFR&lt;60ml/min/1.73m2), known significant bilateral renal artery stenosis or renal
             artery stenosis of a solitary kidney

          -  Sub-study B: Control group 1: with or without RAS blockers, Control group 2: Healthy
             volunteers: concomitant medication with RAS-blockers

          -  Sub-study C: Contraindications Clazakizumab arm: history of gastrointestinal
             perforation, diverticulitis, or inflammatory bowel disease, treatment with an IL-6 or
             IL-6R blocking drug (e.g. tocilizumab, sarilumab, siltuximab) &lt;30 days before study
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Jilma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernd Jilma, MD</last_name>
    <phone>+4314040029810</phone>
    <email>klin-pharmakologie@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian SchÃ¶rgenhofer, MD, PHD</last_name>
    <phone>+4314040029810</phone>
    <email>klin-pharmakologie@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GÃ¼nter Weiss, MD</last_name>
      <phone>+4351250423251</phone>
      <email>guenter.weiss@i-med.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Jilma, MD</last_name>
      <phone>+4314040029810</phone>
      <email>klin-pharmakologie@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Christian SchÃ¶rgenhofer, MD, PHD</last_name>
      <phone>+4314040029810</phone>
      <email>klin-pharmakologie@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg-Christian Funk, MD</last_name>
      <phone>+431491502201</phone>
      <email>georg-christian.funk@wienkav.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMZ SÃ¼d Kaiser Franz Josef Spital</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Zoufaly, MD</last_name>
      <phone>431601912408</phone>
      <email>alexander.zoufaly@wienkav.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KH Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kurt Redlich, MD</last_name>
      <phone>+431801103173</phone>
      <email>kurt.redlich@wienkav.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMZ Baumgartner HÃ¶he Otto Wagner Spital</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Schmied, MD</last_name>
      <phone>+4319106042713</phone>
      <email>brigitte.schmied@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMZ Ost Donauspital</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Stefenelli, MD</last_name>
      <phone>+431288023102</phone>
      <email>thomas.stefenelli@wienkav.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Bernd Jilma</investigator_full_name>
    <investigator_title>Univ.Prof.Dr. Bernd Jilma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymized and pseudonymized data will be published in peer reviewed journals and may be presented at congresses and conferences</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

